a School of Pharmacy , Curtin University , Perth , Australia.
b Curtin Biosciences Research Precinct , Curtin University , Perth , Australia.
J Drug Target. 2018 Aug;26(7):551-562. doi: 10.1080/1061186X.2017.1400552. Epub 2017 Dec 1.
Therapeutic peptides are conventionally administered via subcutaneous injection. Chitosan-based nanoparticles are gaining increased attention for their ability to serve as a carrier for oral delivery of peptides and vaccination. They offered superior biocompatibiltiy, controlled drug release profile and facilitated gastrointestinal (GI) absorption. The encapsulated peptides can withstand enzymatic degradation and various pH. Chitosan-based nanoparticles can also be modified by ligand conjugation to the surface of nanoparticle for transcellular absorption and specific-targeted delivery of macromolecules to the tissue of interest. Current research suggests that chitosan-based nanoparticles can deliver therapeutic peptide for the treatment of several medical conditions such as diabetes, bacterial infection and cancer. This review summarises the role of chitosan in oral nanoparticle delivery and identifies the clinical application of peptide-loaded chitosan-based nanoparticles.
治疗性肽通常通过皮下注射给药。基于壳聚糖的纳米粒子因其能够作为肽的口服递送和疫苗接种载体的能力而受到越来越多的关注。它们具有优越的生物相容性、可控制的药物释放特性，并促进了胃肠道 (GI) 吸收。包封的肽可以抵抗酶的降解和各种 pH 值。基于壳聚糖的纳米粒子还可以通过配体修饰表面来进行细胞间吸收，将大分子特异性靶向递送至感兴趣的组织。目前的研究表明，基于壳聚糖的纳米粒子可以递送治疗性肽，用于治疗多种疾病，如糖尿病、细菌感染和癌症。本文综述了壳聚糖在口服纳米粒子递送上的作用，并确定了载肽壳聚糖基纳米粒子的临床应用。
